N1BI34.SA Neurocrine Biosciences Inc.

Healthcare Pharmaceuticals Sao Paulo Exchange
45.95 BRL
Close of Nov 5, 2026
31.51 45.99
Market cap
BRL 93.0B
P/E
26.1x
P/B
4.65x
ROE
18.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is N1BI34.SA undervalued?

Graham number
Price45.95
Graham value19.78
Premium132.3%

N1BI34.SA trades 132.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neurocrine Biosciences Inc. fundamental analysis

No fundamental analysis for Neurocrine Biosciences Inc. yet.

Neurocrine Biosciences Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neurocrine Biosciences Inc.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under th…

Full company profile